RAD51 and neoplasm: Like in the olaparib arm, individual grafts that responded to CBP were predominantly BRCA1-foci-negative/RAD51-foci-negative (Figures 6A, B) and, interestingly, most grafts of the BRCA-foci-negative/RAD51-foci-positive model b3977, whose response to olaparib was mediocre, showed tumor size reduction under CBP.